Boston Scientific Corporation released its third quarter 2024 earnings report, highlighting a strong performance with net sales increasing 19.4% compared to the same period last year. The company achieved this growth through its various divisions, including MedSurg and Cardiovascular, which saw robust sales increases in key regions like the United States and Europe. The report also details new product approvals and launches, recent acquisitions, and the company's strategic initiatives to drive long-term growth. The company also provided guidance for the fourth quarter and full year 2024, indicating continued optimism about its future performance.